|[Usefulness of N-terminal type B natriuretic propeptide in amyloidosis]|
|Secco A, Ciapponi A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, López A, Rey-Ares L|
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
Secco A, Ciapponi A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, López A, Rey-Ares L. [Usefulness of N-terminal type B natriuretic propeptide in amyloidosis] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rapida No 510. 2017
Evidence of moderate methodological quality shows the usefulness of N-terminal type B natriuretic propeptide in assessing the prognosis in light-chain and transthyretin deposit amyloidosis. Low quality evidence demonstrates its usefulness in assessing treatment response in light-chain amyloidosis. The clinical practice guidelines do recommend it for both indications in light-chain amyloidosis. No health technology assessments were found and the United States health sponsors evaluated do not mention its coverage for that indication.
Final publication URL
Subject indexing assigned by CRD
Amyloidosis; Atrial Natriuretic Factor; Diuretics; Humans
Country of organisation
There is no English language summary available.
Address for correspondence
Institute for Clinical Effectiveness and Health Policy, Viamonte 2146 – 3 Piso, C1056ABH Ciudad de Buenos Aires, Argentina Tel: +54 11 49 66 00 82 Fax:+54 11 49 53 40 58 Email: email@example.com
Date abstract record published